Study guide
10.2 Nutritional and Metabolic Symptoms
Certified Hospice and Palliative Nurse CHPN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Fees, Windows, and Retakes 1.3 Scoring, Test-Day Rules, and Remote Proctoring 1.4 Recertification: HPAR and the Situational Judgment Exercise
2 Chapter 2: Assessment, Goals, and Care Planning
2.1 Goals of Care and Shared Decision Making 2.2 Interdisciplinary Care Planning and Ongoing Evaluation 2.3 Prognostic and Functional Assessment Tools 2.4 Levels of Care and Care-Setting Transitions
3 Chapter 3: Life-Limiting Disease Progression I
3.1 Cancer, Hematologic, and Paraneoplastic Complications 3.2 Heart Failure and Cardiac Disease Progression 3.3 Pulmonary Disease Progression 3.4 Neurologic Disease Progression
4 Chapter 4: Disease Progression II and Imminent Death
4.1 Dementia, Frailty, and Feeding Decisions 4.2 Renal, Hepatic, and Endocrine Trajectories 4.3 Indicators of Imminent Death
5 Chapter 5: Pain Assessment
5.1 Pain Types, Etiology, and Syndromes 5.2 Verbal and Nonverbal Pain Assessment and Scales 5.3 Factors That Influence the Pain Experience
6 Chapter 6: Pharmacologic Pain Management
6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity 6.2 Adjuvant Analgesics 6.3 Titration, Baseline Dosing, and Breakthrough Pain 6.4 Equianalgesic Conversion and Route Changes
7 Chapter 7: Nonpharmacologic Pain and Opioid Safety
7.1 Nonpharmacologic Pain Interventions 7.2 Complementary and Integrative Pain Therapies 7.3 Opioid Adverse Effects, Neurotoxicity, and Rotation
8 Chapter 8: Neurological, Cardiovascular, and Respiratory Symptoms
8.1 Neurological Symptoms 8.2 Delirium and Terminal Restlessness 8.3 Cardiovascular Symptoms 8.4 Respiratory Symptoms: Dyspnea, Cough, and Secretions
9 Chapter 9: Gastrointestinal, Genitourinary, and Musculoskeletal Symptoms
9.1 Gastrointestinal Symptoms 9.2 Genitourinary Symptoms 9.3 Musculoskeletal Symptoms
10 Chapter 10: Skin, Metabolic, Hematologic, and Psychospiritual Symptoms
10.1 Skin and Mucous Membrane Symptoms 10.2 Nutritional and Metabolic Symptoms 10.3 Immune and Hematologic Symptoms 10.4 Psychosocial, Emotional, and Spiritual Symptom Burden
11 Chapter 11: Advance Care Planning, Benefits, and Safety
11.1 Advance Care Planning and Life-Sustaining Therapies 11.2 Hospice and Palliative Benefits under Medicare, Medicaid, and Private Insurance 11.3 Patient Safety: Environmental, Physical, and Socioemotional
12 Chapter 12: Communication, Culture, and Psychosocial Support
12.1 Communication Techniques, Barriers, and Family Meetings 12.2 Cultural Humility and Spiritual Needs 12.3 Psychosocial Needs and IDG Participation
13 Chapter 13: Caregiver Education and Medication Management
13.1 Medication Management and Controlled Substances 13.2 Caregiver and Family Self-Care 13.3 Teaching End-Stage Disease, Pain, and Symptom Plans 13.4 Caregiver Skills, DME, Supplies, and Services
14 Chapter 14: Grief, Death, and End-of-Life Ethics
14.1 Grief, Loss, and Bereavement 14.2 Support at the Time of Death and Post-Mortem Care 14.3 Ethical Issues Related to End of Life
15 Chapter 15: Medicare Hospice Compliance and National Standards
15.1 Medicare Hospice Benefit and Conditions of Participation 15.2 Hospice Eligibility, Admission, and Recertification 15.3 National Hospice and Palliative Care Standards 15.4 National Consensus Project Clinical Practice Guidelines
16 Chapter 16: Legal, Professional Practice, Quality, and Policy
16.1 Legal Regulations: CMS, HIPAA, and OSHA 16.2 Professional Boundaries and Ethics 16.3 QAPI, Self-Care, and Precepting 16.4 Policy, Delivery, and Reimbursement Trends
10.2 Nutritional and Metabolic Symptoms
Key Takeaways Explain This Topic AI
Anorexia-cachexia of advanced disease is cytokine-driven wasting; extra calories and feeding tubes do not reverse it the way true starvation does.
Tube feeding is not the default in advanced dementia or active dying; offer small, frequent, favorite foods and oral comfort instead of forced intake.
Dexamethasone can lift appetite and energy on a short horizon; megestrol may increase appetite but raises thrombosis and edema risk.
Hypercalcemia presents with confusion, constipation, and polyuria; hydrate and consider a bisphosphonate only when that matches goals. Hyponatremia is a separate workup.
Last updated: August 2026
Anorexia-cachexia is not starvation
Families say she is starving. The CHPN nurse has to decide whether the body would use calories if they were forced in. Anorexia-cachexia of advanced disease is a cytokine-driven syndrome: muscle wasting, early satiety, altered taste, and a resting metabolism that does not behave like famine. Offering more food does not rebuild lean mass the way it does in a recovering surgical patient who is otherwise well. Starvation is a lack of access to calories in a body that can still anabolize. That distinction drives every feeding-tube stem on this exam.
Do not make a feeding tube the default. In advanced dementia and in active dying, artificial nutrition does not reliably prevent aspiration, restore strength, or prolong meaningful life. It can add restraints, diarrhea, edema, and a new infection risk. The honest plan is small, frequent, favorite foods , no shame when a plate comes back full, and meticulous mouth care. If the patient still enjoys ice cream at 2 a.m., that is treatment. If the patient turns away from all intake, that is dying physiology, not a nursing failure to spoon harder.
A time-limited trial of assisted feeding is reasonable when goals are uncertain and the patient is not in the last hours. A time-limited trial of a tube is sometimes requested; name the burdens, set a review date, and stop when the tube is not meeting the stated goal. CHPN stems punish the nurse who orders a tube to reverse cachexia and the nurse who withholds all oral pleasure in the name of aspiration risk when the patient is still asking for tastes.
Pharmacologic appetite support, used as a tool
Dexamethasone can improve appetite, energy, and a sense of well-being within days. It is a short-horizon drug: hyperglycemia, insomnia, proximal myopathy, and infection risk accumulate. Use it when prognosis is measured in weeks, not as a forever vitamin.
Megestrol can increase appetite and some weight, much of it fat or fluid. Counsel thrombosis. Patients with prior venous thromboembolism, limited mobility, or pancreatic and other high-clot cancers are poor candidates. Edema and adrenal suppression with prolonged use are additional costs. Megestrol is not a cachexia cure and is not first-line in someone already anticoagulated for a fresh clot.
Other agents appear in practice (mirtazapine for sleep and appetite, cannabinoids for selected patients). Know dexamethasone and megestrol well; they are the exam's usual pair. Never present a stimulant appetite plan as a substitute for explaining the disease.
Hydration as comfort versus edema and secretions
Thirst and dry mouth are not the same as dehydration on a lab printout. A dry mouth is treated with sips, swabs, sprays, and ice chips. Liters of intravenous or subcutaneous fluid will not fix xerostomia if the patient cannot swallow well, and those liters can worsen edema, ascites, pulmonary congestion, and oropharyngeal secretions .
A time-limited hydration trial is fair when delirium might be volume-related, the family wants a trial, and the patient is not drowning in secretions. Write the goal (clearer thinking in 24 to 48 hours). Stop if edema or rattling secretions increase. Do not hydrate solely because a sodium or urea number looks dry if the patient is comfortable and dying.
Hypercalcemia and hyponatremia
Hypercalcemia of malignancy is a CHPN classic: confusion or delirium, constipation, polyuria and polydipsia, fatigue, and sometimes nausea. Bones, groans, stones, and psychiatric overtones still apply. If goals include reversing a treatable delirium, give fluids and consider a bisphosphonate (or denosumab when renal function or prior bisphosphonate failure makes that the better osteoclast block). If the patient is imminently dying and the family has chosen comfort only, treat constipation and delirium as symptoms; do not send the patient to an infusion chair for a calcium number that will not change the dying day.
Hyponatremia is a different map. Syndrome of inappropriate antidiuretic hormone from lung cancer is euvolemic and hypo-osmolar. Mild cases may use fluid restriction if that matches goals. Severe neurologic symptoms may need hypertonic saline only if the goals still include hospital-level correction. In the last days, treat seizures and delirium for comfort rather than chasing a sodium of 118 with intensive care. Do not restrict fluids in a hypovolemic patient who is actually dry, and do not treat hypercalcemia with fluid restriction — that pairing is a common distractor because both cause confusion.
Food as comfort versus medical nutrition
- Question Food as comfort Medical nutrition (tubes, TPN, forced calories)
- What is the goal? Pleasure, taste, social meals, no shame Reverse starvation, heal wounds, prolong life
Does it work in cachexia? It can still give meaning and calories the patient wants It does not reverse cytokine cachexia the way it reverses famine
Typical CHPN plan Small frequent favorites; liberalize diet; mouth care Consider only if a reversible starvation picture and goals support burdens
Hydration partner Sips and oral moisture IV or subcutaneous fluids as a time-limited trial
Stop rule Patient turns away; meal becomes a battle Edema, secretions, agitation, or the stated goal is not met
Exam trap Calling all declined intake a failure to feed PEG as default for advanced dementia or active dying
Walk into a stem with a daughter demanding a percutaneous tube because Dad stopped eating after his third hospitalization for heart failure. Name anorexia-cachexia or organ-failure wasting, offer favorite foods in small amounts, keep the mouth moist, and do not make the tube the required next order. If the same stem adds confusion, constipation, and large urine output in metastatic breast cancer, think hypercalcemia and match fluids plus a bisphosphonate to the goals — not megestrol, and not automatic fluid restriction for SIADH.